Menu
Curie Logo
Donate
  • Home

Clinical trials

Essais cliniques
Search for a clinical trial
Filter

195 result(s)

  • Bladder cancer
    Paris
    MK3475-992
    A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)

    GILLES CREHANGE

  • ENT/Head and Neck Cancers
    Paris
    MK7902-009 (LEAP-009)
    Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

    CHRISTOPHE LE TOURNEAU

  • Breast cancer
    Paris, Saint-Cloud
    MONDRIAN
    Chemotherapy Monitoring by Circulating Tumor DNA (ctDNA) in HER2 (Human Epidermal Growth Factor Receptor-2)- Metastatic Breast Cancer (MONDRIAN): a Phase 2 Study

    FRANCOIS-CLEMENT BIDARD

  • Childhood and adolescent cancers
    Paris
    MS100070-0087
    Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.

    FRANCOIS DOZ

  • Lung cancer
    Paris
    MYTX-011-01
    MYTX-011-01 : A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects with Non-Small Cell Lung Cancer · KisMET-01

    NICOLAS GIRARD

  • ENT/Head and Neck Cancers
    Paris, Saint-Cloud
    NIVOPOST-OP / GORTEC 2018-01
    A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP)

    CHRISTOPHE LE TOURNEAU, LAURENCE BOZEC

  • Lung cancer
    Paris, Saint-Cloud
    PACT-01
    Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.

    CATHERINE DANIEL, MARIE ANGE MASSIANI

  • Paris
    PLUME
    A phase II, monocentric, single arm trial;evaluating the efficacy and safety of;Pembrolizumab in combination with Lenvatinib;in metastatic Uveal MElanoma patients

    MANUEL RODRIGUES

  • Sarcomas
    Paris
    PM1183-C-010-22
    Phase IIb/III, randomized, controlled, open-label study to evaluate lurbinectedin in combination with;doxorubicin versus doxorubicin monotherapy as first-line treatment in patients;suffering from metastatic leiomyosarcoma.

  • Prostate cancer
    Paris
    PRESTO (GETUG-AFU 36)
    Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial

    GILLES CREHANGE

  • Digestive cancers
    Paris, Saint-Cloud
    ProActIF-01
    ProActIF-01 Trial: Randomized phase II study of evaluation of an Individualized Program of nutrition and adapted physical Activity in Frail patients with advanced lung or digestive cancers

    TIMOTHEE MARCHAL

  • Lung cancer
    Paris, Saint-Cloud
    REAL MOOV LUNG
    Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG

    NICOLAS GIRARD

  • Lung cancer
    Paris
    RMC-LUNG-101
    Phase 1b/2 Open-Label, Multicenter Study of RMC-6291 in Combination with Pembrolizumab with or without Chemotherapy, in Patients with KRASG12C-Mutated Solid Tumors

    PAULINE DU RUSQUEC

  • Breast cancer
    Paris, Saint-Cloud
    ROMANCE (RAD05-UC-0107/1803)
    Prospective study of omission of whole-breast radiotherapy following breast-conserving surgery in patients with very low risk ductal carcinoma in situ of the breast

  • Childhood and adolescent cancers
    Paris
    SIOP EPENDYMOMA II
    An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma

    FRANCOIS DOZ

  • Breast cancer
    Paris, Saint-Cloud
    SKYLINE
    Tiragolumab, atezolizumab and chemotherapy in triple negative breast cancer:;A phase II trial.

    FRANCOIS-CLEMENT BIDARD

  • Lung cancer
    Paris
    TAS6417-301
    Randomized, Controlled, Open-label, Phase 3, Global Multi-;Center Trial to Assess the Efficacy and Safety of Zipalertinib;plus Chemotherapy versus Chemotherapy alone, in Patients;with Previously Untreated, Locally Advanced or Metastatic;Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with;Epidermal Growth Factor Receptor (EGFR) Exon 20;Insertion (ex20ins) Mutations.

    NICOLAS GIRARD

  • Prostate cancer
    Paris, Saint-Cloud
    TEMPOS (GETUG P14)
    Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy

    GILLES CREHANGE

  • Paris, Saint-Cloud
    TUMOSPEC (ONCO04) - Paris
    Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.

    DOMINIQUE STOPPA-LYONNET

  • Childhood and adolescent cancers
    Paris
    iMATRIX-Alectinib (GO42286)
    A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.

    FRANCOIS DOZ

  • Breast cancer
    Paris, Saint-Cloud
    TOPOLOGY
    A phase II study to evaluate the efficacy and toxicities;of PLX038, in patients with locally advanced or metastatic triple-negative breast cancer.

    FRANCOIS-CLEMENT BIDARD

  • Cancers gynécologiques
    Paris
    GLORIOSA
    Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA).

    MANUEL RODRIGUES

  • Paris
    DF1001-001
    A Phase I/II, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF1001 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

    EMANUELA ROMANO

  • ENT/Head and Neck Cancers
    Paris
    219885 GALAXIES H&N-202
    A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

    CHRISTOPHE LE TOURNEAU

  • Sarcomas
    Paris
    ADCT-601-102
    A Phase 1b, Open-Label, Dose-Escalation and Dose-Expansion Study to;Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor;Activity of Mipasetamab Uzoptirine (ADCT-601) Monotherapy and in;Combination with Other Anti-Cancer Therapies in Patients with Selected;Advanced Solid Tumors.

  • Lung cancer
    Paris
    AK112-301-HARMONi
    A randomized, double-blind, multi-center, Phase III Study of AK112 or placebo combined with;pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic nonsquamous;NSCLC who have failed to EGFR-TKI treatment.

    NICOLAS GIRARD

  • Breast cancer
    Paris, Saint-Cloud
    ALCINA-2
    Analysis of Circulating Tumor Markers in Blood

    FRANCOIS-CLEMENT BIDARD

  • Paris
    BGB-A317-A3055-101
    A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors.

    CHRISTOPHE LE TOURNEAU

  • Lung cancer
    Paris
    BGB-LC-201
    A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

    NICOLAS GIRARD

  • Lung cancer
    Paris
    BI 1479-0008 (BEAMION LUNG 2)
    Beamion LUNG-2: A Phase III, open-label, randomized, activecontrolled,;multi-centre trial evaluating orally administered;BI 1810631 compared with standard of care as first-line treatment;in patients with unresectable, locally advanced or metastatic nonsquamous;non-small cell lung cancer harbouring HER2 tyrosine;kinase domain mutations.

    NICOLAS GIRARD

<
1 ...7
>